The DOI matches its Crossref record.
Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer
Open accessAbstract
Objectives To determine the efficacy of a three‐fold reduced dose (RD, 27 mg) of intravesical bacille Calmette‐Gue´rin (BCG) against the standard dose (81 mg) in patients with superficial bladder cancer, assessing recurrence, progression and differences in toxicity. Patients and methods Five hundred patients with superficial bladder cancer (Ta, T1, Tis) were enrolled and randomly assigned to be treated after transurethral resection of all visible lesions with intravesical BCG Connaught strain (weekly×six and thereafter fortnightly×six) either with the standard or RD instillation. Results All but one of the 500 patients were evaluable for efficacy and toxicity (252 in the standard arm and 247 in the RD arm). The median follow‐up was 69 months (maximum 104); 71 (28%) patients in the standard arm and 76 (31%) in the RD arm developed recurrences; the median time to recurrence has not yet been attained, but at 5 years the mean ( sd ) percentage of recurrence‐free patients was 70.5 (3.12) and 70.4 (3.1) for the standard and RD arms, respectively. In patients presenting with multifocal tumours, the standard dose was more effective against recurrences than the RD ( P =0.0151). In those with G3 and high‐risk tumours overall, the superiority of the standard dose was marginal ( P =0.060 and P =0.082). Twenty‐nine (11.5%) tumours in the standard arm and 33 (13.3%) in the RD arm progressed to invasive disease; the median time to progression has not yet been attained, but the percentage of progression‐free patients at 5 years was 88.8 (2.23) and 86.9 (2.31) for the standard and RD arms, respectively. The standard dose was more effective than the RD against progression only in patients with multifocal disease ( P =0.048). Twelve (4.8%) cystectomies were performed in the standard and 15 (6.1%) in the RD arm. Currently, 106 (21.2%) patients have died, but only 38 (7.6%) from bladder cancer, i.e. 20 (7.9%) in the standard and 18 (7.5%) in RD arm. Overall the disease‐specific death rate was lower for those patients who completed the scheduled treatment. The cause‐specific survival at 5 years did not differ between the arms ( P =0.76) but there was a trend toward better cause‐specific survival for patients with multifocal tumours in the standard arm. Toxicity differed between the arms, significantly more patients having no toxicity in the RD arm, and fewer having delayed instillations or withdrawing. However, severe systemic toxicity occurred even in patients treated with the RD, in a similar proportion to those receiving the standard dose. Conclusion Overall, the RD gave similar results for recurrence and progression but with significantly less toxicity. However, patients with multifocal tumours fared better with the standard dose and there was a trend towards better recurrence rates in patients with high‐risk tumours. We recommend continuing to use the standard dose for high‐risk tumours, while we consider the reduced dose safe and effective for intermediate‐risk lesions and for maintenance schedules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Babjuk, M., Burger, M., Capoun, O., Cohen, D., Compérat, E. M., Dominguez Escrig, J. L., Gontero, P., Liedberg, F., Masson-Lecomte, A., Mostafid, A. H., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.08.010 · Cited by 1,615
Babjuk, M., Burger, M., Compérat, E. M., Gontero, P., Mostafid, A. H., Palou, J., van Rhijn, B. W. G., Rouprêt, M., Shariat, S. F., Sylvester, R., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.08.016 · Cited by 1,297
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Piñeiro, L., Gonzalez, M., Portillo, J., Ojea, A., Pertusa, C., Rodriguez-Molina, J., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.016 · Cited by 660
Self-citationOddens, J., Brausi, M., Sylvester, R., Bono, A., van de Beek, C., van Andel, G., Gontero, P., Hoeltl, W., Turkeri, L., Marreaud, S., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.10.039 · Cited by 520
Metadata
- Authors
- Martínez‐Pin˜eiro, J. A., Flores, N., Isorna, S., Solsona, E., Sebastián, J. L., Pertusa, C., Rioja, L. A., Martínez‐Pin˜eiro, L., Vela, R., Camacho, J. E., Nogueira, J. L., Pereira, I., Resel, L., Muntan˜ola, P., Galvis, F., Chesa, N., De Torres, J. A., Carballido, J., Bernuy, C., Arribas, S., Madero, R., & Oncológico), F. C. (. U. E. D. T.
- Venue
- BJU International
- Publisher
- Wiley
- Published
- 2002-05
- Volume
- 89
- Issue
- 7
- Pages
- 671-680
- ISSN
- 1464-4096 (ISSN-L)
- 1464-410X
- OpenAlex
- W1578051988
- Cited by
- 217
- References
- 0
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer. https://app.cochat.ai/papers/10.1046/j.1464-410x.2002.02722.x
- The paper
- Martínez‐Pin˜eiro, J. A., Flores, N., Isorna, S., Solsona, E., Sebastián, J. L., Pertusa, C., Rioja, L. A., Martínez‐Pin˜eiro, L., Vela, R., Camacho, J. E., Nogueira, J. L., Pereira, I., Resel, L., Muntan˜ola, P., Galvis, F., Chesa, N., De Torres, J. A., Carballido, J., Bernuy, C., . . . Oncológico), F. C. (. U. E. D. T. (2002). Long‐term follow‐up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette‐Guérin with a reduced dose of 27 mg in superficial bladder cancer. BJU International. https://doi.org/10.1046/j.1464-410x.2002.02722.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.